On July 30, 2025, Hao Yue Capital officially released the "9th Healthcare Investment Excellence Awards." Efung Capital was recognized as "Best Early-Stage Healthcare Investment Institution of the Year" and "Best Innovative Pharmaceutical Investment Institution of the Year." Mr. Zhu Pui, CEO of Efung Capital, was honored as "Young Healthcare Investor of the Year."

Now in its ninth year, the "Healthcare Investment Excellence Awards," meticulously established by Hao Yue Capital, continue to be grounded in the principles of "fairness, justice, openness, and neutrality," providing an in-depth analysis of investment institutions' comprehensive strength across dimensions such as activity in the healthcare industry, transaction volume, return performance, and post-investment empowerment. The awards simultaneously focus on five core tracks—Innovative Pharmaceuticals, Innovative Medical Devices, IVD and Life Sciences, Health Services and Smart Healthcare, and Biotechnology—selecting benchmark enterprises and investment forces of the year, dedicated to establishing value benchmarks for the industry and driving ecosystem co-prosperity.

In the core track of biotechnology, a field brimming with potential, Efung Capital has focused on investments in original drugs and high-end medical devices since its inception. In the past two years, Efung Capital has participated in the financing of over a dozen companies in the biopharmaceutical sector, continuously exploring the potential of high-quality projects.

Navigating through cycles, a warm current surges. In 2025, China's healthcare industry is undergoing a structural recovery through deep refinement. In the first half of the year, financing activity across various tracks steadily increased, with several landmark major transactions successfully concluded. A series of "hardcore" innovation cases have not only injected a boost of confidence into the market but also signaled that China's medical innovation has officially entered a new stage defined by high quality, internationalization, and value-driven growth.

Gather broadly but choose selectively; accumulate richly but release sparingly. Efung Capital will continue to deeply cultivate the biopharmaceutical field, empowering outstanding enterprises with professional investment capabilities and industrial resources. We firmly believe that harsh winters test true mettle, while warm springs nurture new life. Efung Capital is eager to join hands with Hao Yue Capital and all industry colleagues, leveraging the power of "excellence" to embark on a new journey, contributing surging momentum to the elevated development of China's healthcare industry!